Pscilly

Psilocybin for Veterans: House Panel Presses VA on Readiness

By · Published

Congress put the Department of Veterans Affairs on the spot Wednesday over a simple question: if psilocybin or another psychedelic treatment wins federal approval next year, will the VA be ready to offer it?

The House Veterans' Affairs Subcommittee on Health held an oversight hearing on Nov. 18 titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward." Lawmakers heard from VA leadership, university researchers and veterans' organizations about where the science stands and what it will take to move from clinical trials to everyday care.

A chairwoman asks whether VA will be ready

Subcommittee Chairwoman Mariannette Miller-Meeks, an Iowa Republican who is a physician and a 24-year Army veteran, opened by pointing to the VA's own suicide prevention data. Her prepared remarks noted an average of 17 veteran suicides a day in 2024, more than 6,400 in a single year, a figure she said has barely moved despite years of federal effort.

Miller-Meeks said some psychedelic therapies are far enough along that one could win FDA approval within the next year. She asked whether the VA will have trained clinicians, suitable facilities and clinical protocols in place, and whether a veteran's access would depend on where they live. She also said the VA, the Department of Health and Human Services, the FDA, the DEA and the Justice Department will need to coordinate on scheduling, registration and distribution rules. In her view, community providers may need to help where VA medical centers lack staff or space.

The VA's research and readiness plan

Andrew Gradison, senior advisor to the under secretary for health at the Veterans Health Administration, said in written testimony that the VA had 21 active clinical studies of psychedelic treatments for mental health conditions as of September 2026. Those studies cover MDMA, psilocybin, DMT and LSD. He highlighted a psilocybin trial the VA launched on Aug. 5 for veterans with major depressive disorder, including those who also have PTSD.

Gradison tied the department's expanding research to Executive Order 14401, signed in April. He said the order calls for prioritizing breakthrough-designated psychedelic drugs for review, encouraging lawful access through the federal Right to Try law, increasing trial participation and data sharing, and speeding possible rescheduling after successful Phase 3 trials. The VA and HHS signed a five-year agreement on July 13 to cooperate on psychedelic trials, and the VA signed a separate information-sharing agreement with the FDA.

Most notably, Gradison said the VA has already picked 10 facilities to serve as early implementers, educators or sites-in-training if treatments are approved. He said the VA chose them because their teams have experience with psychedelic research protocols, and that lessons from those sites will guide a phased expansion. The VA's stated goal is to be the first health care system in the country to deliver these treatments, but Gradison stressed that it will begin clinical use only after all regulatory approvals are complete. He added that the department strongly discourages veterans from self-medicating with psychedelics or any unprescribed substance.

Miller-Meeks also cited the VA's first MDMA-assisted therapy trial for veterans with PTSD and alcohol use disorder, which moved into a randomized trial this year at VA facilities in Rhode Island and Connecticut. Providence VA Medical Center is Rhode Island's VA hospital.

Researchers and advocates weigh in

Mark Niciu, an assistant professor of psychiatry who helps lead the University of Iowa Psychedelics Research Program, told the panel that functional unblinding is a major challenge in psychedelic research. Because participants can usually tell whether they received an active drug, results can be skewed. His team ran a small pilot study in men with alcohol use disorder that compared psilocybin with ketamine, two drugs with noticeable effects, to test a design that could make blinding more credible.

Other written statements urged the VA to set firm milestones. Testimony from one physician witness asked Congress to require the VA to report on clinical readiness, track who receives treatment and who cannot get it, and monitor long-term outcomes and harms. Another witness noted that both COMPASS Pathways and Usona Institute have psilocybin applications before the FDA. The Special Forces Foundation, in a statement for the record, put the cost of psychedelic therapy abroad at about $8,000 per veteran and asked the subcommittee to press the VA to pilot at-home ketamine care for veterans far from clinics.

What comes next

A hearing does not change the law, but it creates a public record that can shape future legislation, spending language and oversight of the VA. With the first psilocybin approval decisions possible in 2027, lawmakers signaled they expect the department to have its sites, staff and safety standards in place before that day arrives.

On Pscilly

Published
November 18, 2026